7 completed, 2 recruiting, 1 active not recruiting, 1 enrolling by invitation. 13 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 7, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| [11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan - Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild | Phase 1 | Not yet recruiting | Stony Brook University | 18 | 2026-10-01 | 2026-10-02 |
| A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction HJB647 low dose, HJB647 high dose, Placebo - Heart Failure With Reduced Ejection Fraction | Phase 1 | Recruiting | Novartis Pharmaceuticals | 12 | 2026-03-18 | 2026-10-01 |
| Whole Heart Radiotherapy for End-stage Heart Failure Whole Heart Radiation Therapy - Heart Failure NYHA Class III, Heart Failure NYHA Class IV | Phase 1 | Enrolling by invitation | McGill University Health Centre/Research Institute of the McGill University Health Centre | 6 | 2025-04-30 | 2025-05-14 |
| Study Assessing Left Ventricular Administration of a Genetic Medicine Directing Organ Regeneration in Heart Failure YAP101 (AAV9-Sav-shRNA) - Heart Failure With Reduced Ejection Fraction | Phase 1 | Recruiting | Medley Therapeutics | 24 | 2025-04-23 | 2025-04-27 |
| Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka HFrEF Polypill, Comparator Arm - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Washington University School of Medicine | 40 | 2025-02-15 | 2025-05-08 |
| A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure Danicamtiv, Midazolam - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Bristol-Myers Squibb | 13 | 2023-08-17 | 2024-04-04 |
| Ketone Pharmacokinetic Study in HFrEF DeltaG (250 mg/kg), DeltaG (500 mg/kg) - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Duke University | 20 | 2023-06-02 | 2024-12-27 |
| Treatment of Non-ischemic Cardiomyopathies by Intravenous Extracellular Vesicles of Cardiovascular Progenitor Cells Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells - Heart Failure With Reduced Ejection Fraction | Phase 1 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 11 | 2023-05-31 | 2026-07-08 |
| Phase Ib/IIa Trial With AC01 in Patients With HFrEF AC01, Placebo Minitablets - Heart Failure With Reduced Ejection Fraction | Phase 1 / Phase 2 | Completed | AnaCardio AB | 58 | 2023-02-23 | 2026-05-07 |
| Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) JK07, Matching Placebo - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Salubris Biotherapeutics Inc | 14 | 2020-09-21 | 2025-07-09 |
| First in Humans to Evaluate Collagen Patches With Stem Cells in Patients With Ischemic Left Ventricular Dysfunction VB-C01 - Heart Failure With Reduced Ejection Fraction | Phase 1 | Unknown | Viscofan | 10 | 2018-11-13 | 2018-11-20 |
| Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial Thiamine, Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Hamilton Health Sciences Corporation | 24 | 2018-04-02 | 2021-08-31 |
| v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 MYK-491, Placebo - Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 52 | 2018-02-06 | 2023-02-02 |
Heart Failure (7) · Cardiomyopathy, Dilated (1) · Cognitive Dysfunction (1) · Dementia (1) · Encephalitis (1) · Fibromatosis, Gingival, 2 (1) · Ketosis (1) · Neuroinflammatory Diseases (1) · Thiamine Deficiency (1)
Cardiovascular Diseases (8) · Heart Diseases (8) · Nutritional and Metabolic Diseases (2) · Acid-Base Imbalance (1) · Acidosis (1) · Avitaminosis (1) · Brain Diseases (1) · Cardiomegaly (1) · Cardiomyopathies (1) · Central Nervous System Diseases (1) · Cognition Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Deficiency Diseases (1) · Genetic Diseases, Inborn (1) · Inflammation (1)
11C-PS13 (1) · Midazolam (1) · Thiamine (1) · sacubitril and valsartan sodium hydrate drug combination (1)
Bristol-Myers Squibb (2) · AnaCardio AB (1) · Assistance Publique - Hôpitaux de Paris (1) · Duke University (1) · Hamilton Health Sciences Corporation (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Medley Therapeutics (1) · Novartis Pharmaceuticals (1) · Salubris Biotherapeutics Inc (1) · Stony Brook University (1) · Viscofan (1) · Washington University School of Medicine (1)
United States (7) · Canada (3) · France (2) · Netherlands (2) · Sweden (2) · United Kingdom (2) · Germany (1) · Italy (1) · Poland (1) · Spain (1) · Sri Lanka (1)
Alexander Postalian, MD (1) · Eric KC Wong, MD FRCPC (1) · Ian J Gerard, MD, PhD (1) · Lars H Lund, MD PhD (1) · Martin L Bernier, MD (1) · Senthil Selvaraj, MD, MSTR, MA (1) · Tarek Hijal, MD (1) · Wilson Tang, MD (1)
PMID 30258648, PMID 40139871, PMID 40664424, PMID 40737710, PMID 40831309, PMID 42341796
K23HL161348 (1), R21AG102953 (1)